Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Clasificación en acciones #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Precio por acción
$0.0416118
Capitalización bursátil
$12.78M
Cambio (1 día)
1.72%
Cambio (1 año)
-22.01%
País
AU
Comercio Noxopharm Limited (NOX)

Categoría

Healthcare
Historial de desdoblamientos de acciones de Noxopharm Limited (NOX)
La acción Noxopharm Limited (símbolo: NOX) tuvo un total de 1 desdoblamientos.
El desdoblamiento más reciente ocurrió el May 19, 2020.
Una acción NOX comprada antes de May 19, 2020 equivaldría hoy a 1.132 acciones NOX.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
2020-05-19 283:250 x1.132 x1.132
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5 x199
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 0 -
US
UCB SA UCB SA
UCB SA
UCB.BR
 0 -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU